Journal of Cancer Genetics and Biomarkers
Publishing rigorous molecular and computational studies in cancer genetics and biomarker validation.
Mission & Vision
The Journal of Cancer Genetics and Biomarkers (JCGB) publishes high-quality research that advances understanding of cancer genomics, biomarker discovery, and their translation into clinical practice. We emphasize methodological rigor, reproducibility, and ethical stewardship of genomic data. Our vision is to accelerate precision oncology by disseminating science that directly informs diagnosis, prognosis, and therapy.
Cancer Genomics
Germline predisposition, somatic mutation landscapes, chromothripsis, mutational signatures, DNA repair deficiencies, and chromatin remodeling.
Biomarker Discovery & Validation
Multi-tier validation from in silico discovery through analytical and clinical validation, including ctDNA, cfRNA, exosomes, and metabolic signatures.
Tumor Microenvironment
Immune cell infiltration, cytokine networks, microbiome interactions, stromal remodeling, angiogenesis, and metabolic competition.
Multi-Omic Integration
Systems approaches integrating genomics, transcriptomics, proteomics, metabolomics, and radiomics to generate comprehensive tumor atlases.
Liquid Biopsy
Non-invasive diagnostics including circulating tumor cells, cell-free DNA/RNA, exosomes, and metabolite-based assays.
Precision Therapeutics
Linking genomic alterations to therapy selection, resistance mechanisms, and adaptive trial designs.
JCGB welcomes computational innovations that drive discovery at scale. We prioritize machine learning algorithms, predictive models, and decision-support tools that integrate genomics, proteomics, pathology, imaging, and electronic health records. Manuscripts must demonstrate interpretability, clinical relevance, and adherence to data governance best practices.
Research in data harmonization, federated learning, privacy-preserving analytics, and bioinformatics pipelines that enable reproducible cancer genomics research. We encourage submissions discussing bias mitigation and sustainable data stewardship frameworks.
JCGB publishes pragmatic clinical trials, real-world evidence studies, implementation science, and decision-analysis models that highlight barriers and enablers to biomarker adoption. Topics include reimbursement pathways, laboratory accreditation, and electronic decision support.
We seek frameworks for informed consent, data sovereignty, community engagement, and culturally competent genomic counseling. Manuscripts addressing algorithmic bias, sustainable biobanking, cross-border data transfer, and benefit sharing with underrepresented communities are encouraged.
JCGB is not the ideal venue for manuscripts that:
- Focus exclusively on preclinical drug screening without genomic or biomarker context.
- Lack novel insight into cancer-specific mechanisms or biomarker performance.
- Do not provide adequate statistical power, validation, or reproducibility evidence.
- Report purely descriptive case studies lacking molecular analysis or translational inference.
- Apply standard machine learning / AI to small datasets without significant methodological novelty.
- Are primarily epidemiological or lack molecular/genomic/biomarker analysis.
Original Research
Comprehensive studies presenting new experimental data, computational discoveries, or translational insights supported by robust methodology and validation.
Rapid Communications
High-impact findings requiring swift dissemination—such as emergent resistance mechanisms, novel biomarkers, or urgent public health relevance—presented concisely with strong evidence.
Reviews & Meta-Analyses
State-of-the-art syntheses that map progress, identify gaps, and chart future directions in specific domains (e.g., organ-specific biomarker strategies, AI in pathology).
Methods & Protocols
Detailed experimental or computational methods, benchmarking studies, and protocol standardisations that enable reproducible research and clinical translation.
Clinical Case Series
Carefully documented cases illustrating biomarker-driven decision-making, therapy adaptation, or novel diagnostic use in real-world oncology practice.
Policy & Perspective Pieces
Thought leadership addressing policy shifts, regulatory landscapes, ethical dilemmas, equity considerations, and cross-sector collaboration models.
JCGB emphasizes methodological rigor, reproducibility, and ethical stewardship. Before submission, confirm:
- Your manuscript directly addresses at least one JCGB scope domain with explicit mention in the abstract and keywords.
- Experimental design includes validation strategies (technical replicates, orthogonal methods, independent cohorts, or computational benchmarks).
- You have documented ethical approvals, consent procedures, and data management plans.
- Figures, tables, and supplemental files provide full transparency for reanalysis.
- Your discussion articulates translational relevance, implementation considerations, or policy implications.
JCGB emphasizes the following core areas. Authors are encouraged to align submissions with these domains:
- Cancer genomics
- Somatic mutation landscapes
- Germline predisposition
- Clonal evolution
- Epigenetic reprogramming
- Single-cell sequencing
- Spatial transcriptomics
- Liquid biopsy
- Circulating tumor DNA
- Minimal residual disease
- Tumor immune microenvironment
- Neoantigen prediction
- Checkpoint inhibition
- CAR-T therapy biomarkers
- Precision radiomics
- Digital pathology
- Machine learning oncology
- Explainable AI
- Multi-omics integration
- Proteomic signatures
- Metabolomic profiling
- Exosomal biomarkers
- Tumor heterogeneity
- Adaptive clinical trials
- Synthetic lethality
- Drug resistance mechanisms
- Pharmacogenomics
- Real-world evidence
- Health technology assessment
- Genomic data ethics
- Indigenous genomic data
- Biobanking governance
- AI fairness
- Population genomics
- Cancer disparities
- Implementation science
- Precision public health
- CRISPR screening
- Functional genomics
- Radiogenomics
- Bioinformatics pipelines
- Data harmonisation
- Federated learning
- Privacy-preserving analytics
- Electronic health records
- Clinical decision support
- Patient-reported outcomes
- Cost-effectiveness
- Regulatory science
- Reimbursement models
- Biomarker qualification
- Diagnostic stewardship
- Oncology informatics
- AI governance
- Equitable precision medicine
- Cancer survivorship biomarkers
- Systems oncology
- Metabolic competition
- Immune evasion
- Translational biomarker research
JCGB welcomes proposals that align with the scope domains described above. Special issues should demonstrate clear objectives, timeliness, expert guest editors, and a recruitment plan that fosters diversity in geography, gender, and career stage. Visit the Proposing a Special Issue page for guidance on structuring proposals, timelines, and APC considerations.
Align Your Research with JCGB
Ready to contribute to a journal dedicated to the frontiers of cancer genetics and biomarker science? Review the author guidelines, refine your keywords, and submit today.
Last updated: September 2025. JCGB revisits its scope annually to ensure alignment with emerging scientific discoveries, technological advances, and community needs. Scope revisions are guided by editorial board feedback and community input to maintain alignment with advances in cancer genomics / biomarker research.